Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.64 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853946 | 1.00 | HCRTR1 (0.64) | HCRTR1HCRTR2USP30UCHL1JAK2 | |
| SCHEMBL21065161 | 0.91 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL21065207 | 0.91 | HCRTR2 (0.65) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL21065162 | 0.91 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL21065206 | 0.91 | HCRTR2 (0.65) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3916610 | 0.89 | HCRTR1 (0.53) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3916612 | 0.89 | HCRTR1 (0.53) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3852302 | 0.88 | HCRTR1 (0.50) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3852298 | 0.88 | HCRTR1 (0.50) | HCRTR1HCRTR2USP30UCHL1POLB | |
| SCHEMBL3922427 | 0.86 | HCRTR1 (0.49) | HCRTR1HCRTR2USP30UCHL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-7579349-B2 | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | HCRTR1 3664/4885HCRTR2 3725/4885USP30 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.